Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges.

Serris A, Danion F, Benzakoun J, Tattevin P, Gangneux JP, Verdon R, Bonhomme J, Lelièvre L, Tandjaoui-Lambiotte Y, Braun T, Talarmin JP, Desoubeaux G, Aguilar C, Lortholary O, Ghez D, Lanternier F, CEREALS study group

Open source

DOI: 10.1093/jac/dkag266
Published: 2026 Aug 4
Container: The Journal of antimicrobial chemotherapy
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/jac/dkag266,
  title = {Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges.},
  author = {Serris A and Danion F and Benzakoun J and Tattevin P and Gangneux JP and Verdon R and Bonhomme J and Lelièvre L and Tandjaoui-Lambiotte Y and Braun T and Talarmin JP and Desoubeaux G and Aguilar C and Lortholary O and Ghez D and Lanternier F and CEREALS study group},
  year = {2026},
  journal = {The Journal of antimicrobial chemotherapy},
  doi = {10.1093/jac/dkag266},
  url = {https://doi.org/10.1093/jac/dkag266}
}

RIS

TY  - JOUR
TI  - Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges.
AU  - Serris A
AU  - Danion F
AU  - Benzakoun J
AU  - Tattevin P
AU  - Gangneux JP
AU  - Verdon R
AU  - Bonhomme J
AU  - Lelièvre L
AU  - Tandjaoui-Lambiotte Y
AU  - Braun T
AU  - Talarmin JP
AU  - Desoubeaux G
AU  - Aguilar C
AU  - Lortholary O
AU  - Ghez D
AU  - Lanternier F
AU  - CEREALS study group
PY  - 2026
JO  - The Journal of antimicrobial chemotherapy
DO  - 10.1093/jac/dkag266
UR  - https://doi.org/10.1093/jac/dkag266
ER  -

APA

A, S., F, D., J, B., P, T., JP, G., R, V., J, B., L, L., Y, T., T, B., JP, T., G, D., C, A., O, L., D, G., F, L., & group, C. S. (2026). Cerebral aspergillosis under ibrutinib therapy: clinical features and management challenges.. The Journal of antimicrobial chemotherapy. https://doi.org/10.1093/jac/dkag266

Source records

pubmed · retrieved 2026-09-26T09:09:09.157Z